The expression of the receptor for advanced glycation end-products (RAGE) in RA-FLS is induced by IL-17 via Act-1 by Heo, Yu-Jung et al.
RESEARCH ARTICLE Open Access
The expression of the receptor for advanced
glycation end-products (RAGE) in RA-FLS is
induced by IL-17 via Act-1
Yu-Jung Heo
1†, Hye-Jwa Oh









1 and Ho-Youn Kim
1
Abstract
Introduction: The receptor for advanced glycation end-products (RAGE) has been implicated in the pathogenesis
of arthritis. We conducted this study to determine the effect of interleukin (IL)-17 on the expression and
production of RAGE in fibroblast-like synoviocytes (FLS) from patients with rheumatoid arthritis (RA). The role of
nuclear factor-B (NF-B) activator 1 (Act1) in IL-17-induced RAGE expression in RA-FLS was also evaluated.
Methods: RAGE expression in synovial tissues was assessed by immunohistochemical staining. RAGE mRNA
production was determined by real-time polymerase chain reaction. Act-1 short hairpin RNA (shRNA) was produced
and treated to evaluate the role of Act-1 on RAGE production.
Results: RAGE, IL-17, and Act-1 expression increased in RA synovium compared to osteoarthritis synovium. RAGE
expression and production increased by IL-17 and IL-1b (*P< 0.05 vs. untreated cells) treatment but not by tumor
necrosis factor (TNF)-a in RA-FLS. The combined stimuli of both IL-17 and IL-1b significantly increased RAGE
production compared to a single stimulus with IL-17 or IL-1b alone (P< 0.05 vs. 10 ng/ml IL-17). Act-1 shRNA
added to the RA-FLS culture supernatant completely suppressed the enhanced production of RAGE induced by IL-
17.
Conclusions: RAGE was overexpressed in RA synovial tissues, and RAGE production was stimulated by IL-17 and IL-
1b. Act-1 contributed to the stimulatory effect of IL-17 on RAGE production, suggesting a possible inhibitory target
for RA treatment.
Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune
disease characterized by chronic synovial inflammation,
which ultimately leads to the destruction of cartilage
and bone in the affected joints. Synovial hyperplasia is a
hallmark pathology of RA, and fibroblast-like synovio-
cytes (FLS) play a critical role in RA pathogenesis by
producing pro-inflammatory soluble factors or activating
other immune cells.
The receptor for advanced glycation end-products
(RAGE) is a novel receptor that binds products of none-
nzymatic glycation of proteins or advanced glycation
end-products (AGEs) [1]. AGEs are a heterogeneous
group of irreversible products formed from the none-
nzymatic reaction of reducing sugars [2]. AGEs accumu-
late under a wide variety of biological conditions, such
as diabetes, renal failure, aging, and inflammation [3].
The interaction of AGE and RAGE has been implicated
in the activation of inflammatory signaling cascades and
sequelae of AGE accumulation, such as diabetic compli-
cations, amplification of inflammation, and tissue injury
[3]. AGEs cannot be removed until the protein degrades,
and they alter tissue integrity and metabolism. Several
receptors for the AGEs are known, and RAGE is a cen-
tral signal transduction receptor for AGEs. RAGE is a
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surface receptors [4]. This receptor is strongly activated
by cross-linked AGE-modified proteins. The activation
of RAGE results in activation of an inflammatory signal-
ing cascade, and up-regulation of RAGE is associated
with sustained cellular perturbation and tissue injury
[5]. Up-regulation of RAGE has also been reported
under various pathologic conditions, such as vascular
injury, diabetes, neurodegenerative disorders, and
inflammatory diseases [6]. Overexpression of RAGE is
implicated in the pathogenesis of RA. RAGE is overex-
pressed in synovial macrophages obtained from patients
with RA, and synovial tissue cell culture supernatants
strongly induce cell surface RAGE [7]. The increased
level of RAGE pro-inflammatory ligands, such as high-
mobility group box chromosomal protein 1 (HMBG-1)
and S100/calgranulin in serum and synovial fluid in
patients with RA may contribute to RAGE up-regulation
[8,9].
Interleukin (IL)-17 and its major cell source, the type
17 T helper cells (Th17), have been implicated in the
pathogenesis of various inflammatory diseases [10,11].
IL-17 mediates inflammatory responses including angio-
genesis, recruitment of inflammatory cells, and induc-
tion of pro-inflammatory mediators in endothelial and
epithelial tissues [12]. An up-regulated Th17 response
or increased IL-17 production is associated with the
pathogenesis of autoimmune diseases and chronic
inflammation, including RA [13,14]. IL-17 mediates cru-
cial cross talk between the immune system and tissues.
Signaling through IL-17 receptors on synoviocytes
induces immune cells to produce inflammatory factors
such as IL-1 and IL-6 [15]. Many studies have been con-
ducted regarding signaling molecules under IL-17 recep-
tors, and nuclear factor-B (NF-B) activator 1 (Act1) is
considered an essential protein for linking IL-17 recep-
tors and downstream signaling pathways. Act1 is a
recently identified 60-kD cytoplasmic adaptor protein
that activates IB kinase (IKK), liberating NF-Bf r o m
its complex with IB [16].
We investigated whether pro-inflammatory cytokines,
including IL-1, tumor necrosis factor (TNF)-a,a n d
especially IL-17, can induce RAGE expression and pro-
duction in RA-FLS. We also determined whether the sti-
mulatory effect of IL-17 on RAGE is mediated by Act-1.
Materials and methods
Patients
Human FLSs were isolated from synovial tissues from
patients with RA (F/M 7/1, median age 56 (range 26 to
65)), and patients with OA (F/M 6/1, median age 64
(range 46 to 71)) at the time of knee-joint arthroscopic
synovectomy, as described previously [17]. The RA
patients were all taking DMARDs (disease modifying
anti-rheumatic drugs) and the rheumatoid factor was
positive in five patients. ESR (erythrocyte segmentation
rate), and CRP (C-reactive protein) checked pre-opera-
tively were median 34 (range: 12 to 84) mm/hr and
median 1.22 (range: 0.08 to 5.94) mg/dL respectively.
The diagnosis of RA was confirmed by the revised cri-
teria of the American College of Rheumatology [18].
Informed consent was provided according to the
Declaration of Helsinki and obtained from all patients.
Approval by the ethical committee of the Seoul St.
Mary’s Hospital (Seoul, Korea) was obtained.
Isolation and culture of FLS
Synoviocytes were isolated by enzymatic digestion of
synovial tissue specimens obtained from patients with
RA undergoing total joint replacement surgery. The tis-
sue samples were minced into 2- to 3-mm pieces and
treated for four hours with 4 mg/ml type I collagenase
(Worthington Biochemical Company, Freehold, NJ,
USA) in Dulbecco’s modified Eagle’s medium (DMEM)
at 37°C in 5% CO2. Dissociated cells were then centri-
fuged at 500 × g and resuspended in 10% fetal bovine
serum in DMEM. After an overnight culture, the non-
adherent cells were removed, and the adherent cells
were cultured in DMEM supplemented with 20% fetal
calf serum. Synoviocytes from passages 4 to 8 were used
in each experiment. The RA-FLS were incubated with
IL-17, IL-1b,o rT N F - a (R&D Systems, Minneapolis,
MN, USA) alone and in combination. To evaluate signal
transduction, the RA-FLS were pretreated with 20 μM
LY294002, 50 μM AG490, 10 μM SB203580, 20 μM
PD98059, 10 μM parthenolide, or 10 μMc u r c u m i na n d
then treated with IL-17 for 12 h. The inhibitors were
purchased from Calbiochem (Schwalbach, Germany).
Immunohistochemistry of RA synovium and FLS
Immunohistochemical staining was performed on sec-
tions of synovium. Briefly, the synovial samples were
obtained from eight patients with RA and one patient
with osteoarthritis (OA) and fixed in 4% paraformalde-
hyde solution overnight at 4°C, dehydrated with alcohol,
washed, embedded in paraffin, and sectioned into 7-μm-
thick slices. The sections were depleted of endogenous
peroxidase activity by adding methanolic hydrogen per-
oxide (H2O2) and were blocked with normal serum for
30 minutes. After an overnight incubation at 4°C with
goat anti-human RAGE, anti-Act1 antibody (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and antihuman IL-
17 antibody (R&D Systems), pS727-STAT3, p-AKT, and
p-C-Jun (Cell Signaling Technology, Danvers, MA, USA),
the samples were incubated with the secondary antibo-
dies, biotinylated anti-goat IgG and anti-rabbit IgG for 20
minutes. The sections were then incubated with strepta-
vidin-peroxidase complex (Vector Laboratories Ltd.,
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with 3, 3-diaminobenzidine (DAKO, Glostrup, Denmark).
The sections were counterstained with hematoxylin, and
the samples were photographed with a photomicroscope
(Olympus, Tokyo, Japan). Infiltrated inflammation cells
of synovium histology grading system are classified and
400 magnification microscope observations set the num-
ber of positive cells at the site. We used the immunohis-
tological criteria for classification of synovial tissues into
“mild” and “severe”. We evaluated the severity by the
method presented in reference 20.
Dual immunohistochemical labelling (RAGE and
CD55, CD68, P-STAT3, P-IKB, P-C-JUN, P-AKT) was
performed using the DakoCytomation EnVision Double-
stain-Kit (code K1395; DAKO North America, Inc. Car-
pinteria, CA, USA) according to the manufacturer’s
instructions [19]. In brief, the synovial tissue was incu-
bated with the first primary antibody (anti-RAGE, Santa
Cruz Biotechnology, Inc) and polymer method, develop-
ing the final color product using AEC (DAKO). The sec-
ond primary antibody (anti-CD55, Serotec, Kidlington,
Oxford, UK to detect fibroblast-like synoviocytes (FLS);
anti-CD68, DAKO to detect macrophages; anti p-
STAT3, p-IKB, p-c JUN, p-AKT) was placed on the sec-
tions at RT for one hour, followed by a standard immu-
nohisto-chemical alkaline phosphatase method, to
develop a color reaction with fast blue. No counterstain
was used and the sections were mounted in an aqueous
mounting medium. Samples were photographed with an
Olympus photomicroscope (Tokyo, Japan)
Real-time PCR for RAGE and Act-1
After the incubation, total mRNA was extracted from
RA-FLS using RNAzol-B (Biotecx, Houston, TX, USA)
according to the manufacturer’s instructions. Reverse
transcription of 2 μg of total mRNA was conducted at
42°C using the Superscript reverse transcription system
(Takara, Shiga, Japan). Expression of the RAGE and
Act-1 was determined by real time PCR with SYBR
Green I (Roche Diagnostic, Mannheim, Germany). Each
quantitative real-time PCR reaction was performed
using 10 μL of SYBR green reaction mix (TAKARA
SYBR Premix; Takara, Shiga, Japan), 200 nM of each
primer RAGE and Act, 2 μL of template, and made up
to 20 μL with sterile water in capillary tubes. All real-
time reactions (standards, unknown samples, and con-
trols) were performed in triplicate. The following pri-
mers were used for each molecule: for RAGE, 5’-CAG-
TAG-CTC-CTG-GTG-GAA-CCG-TAA-C-3’ (sense)
and 5’-CCT ATC TCA GGG AGG ATC AGC ACA G-
3’ (antisense); for Act-1, 5’-GCA TTC CTG TGG AGG
TTG AT-3’ (sense) and 5’- GTC TCC GGA GGA ATT
GTG AA-3’ (antisense); for b-actin, 5’-GGA CTT CGA
GCA AGA GAT GG-3’ (sense) and 5’-TGT GTT GGC
GAT CAG GTC TTT G-3’ (antisense) in a LightCy-
clerÔ (Roche Diagnostics, Mannheim, Germany). The
relative expression levels were calculated by normalizing
the targets to the endogenously expressed housekeeping
gene (b-actin). Melting curve analysis was performed
immediately after the amplification protocol under the
following conditions: 0 s (hold time) at 95°C, 15 s at 65°
C, and 0 s (hold time) at 95°C. The temperature change
rate was 20°C/s except in the final step, when it was 0.1°
C/s. The crossing point (Cp)w a sd e f i n e da st h em a x i -
mum of the second derivative from the fluorescence
curve.
Transfection of Act-1 short hairpin RNA (shRNA)
A hairpin oligonucleotide sequence targeting human
ACT-1 (target sequence: 5’-GAGGCATTGATATCAT-
TAA-3’) was purchased from Dharmacon (Rockford, IL,
USA). RA-FLS were plated in 60-mm dishes and trans-
fected with 100 nM shRNA or 100 nM negative control
vector using HiPerFect Transfection Reagent (Qiagen,
Valencia, CA, USA), according to the manufacturer’s
protocol.
Western blot for RAGE, signal transduction molecules,
and their phosphor form
RA-FLS were incubated with LY294002, partherolide, or
AG490 in the presence or absence of 10 ng/ml IL-17.
After a one-hour culture, the cells were lysed. Protein
concentrations in the supernatants were determined
using the Bradford method (Bio-Rad, Hercules, CA,
USA). Protein samples were separated with 10% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and
transferred to a nitrocellulose membrane (Amersham
Pharmacia, Piscataway, NJ, USA). For Western hybridi-
zation, the membrane was pre-incubated with skim milk
buffer (0.1% skim milk in 0.1% Tween 20 in Tris-buf-
fered saline) for two hours, followed by incubation in
primary Akt antibodies, phosphorylated Akt, IB-a,
phosphorylated IB-a, STAT3, phosphorylated STAT3,
c-Jun, phosphorylated c-Jun (Cell Signaling Technology),
or RAGE (Santa Cruz Biotechnology) for one hour at
room temperature. Horseradish peroxidase-conjugated
secondary antibodies were added and the membranes
were incubated for 30 minutes at room temperature.
The hybridized bands were detected using the ECL
detection kit and Hyperfilm-ECL reagents (Amersham
Pharmacia).
Determination of concentration of RAGE by sandwich
enzyme-linked immunosorbent assays (ELISA)
The concentrations of RAGE in culture supernatants
were measured using an enzyme-linked immunosorbent
assay (ELISA) following the manufacturer’si n s t r u c t i o n s
(R&D Systems).
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Toxicity of the stimulated RA-FLS was assessed using
the lactate dehydrogenase (LDH) release assay. The cells
were collected by centrifugation, and each pellet was
mixed with 0.05% trypan blue. The proportion of cells
containing trypan blue was determined microscopically.
The LDH activity was measured in culture supernatants
using the QuantiChromÔ lactate dehydrogenase kit
(BioAssay Systems, Hayward, CA, USA) according to
the manufacturer’s protocol.
Statistical analysis
All data are expressed as the mean ± SD. The statistical
analysis was performed using SPSS 10.0 for Windows
(SPSS Inc., Chicago, IL, USA). The differences between
groups were analyzed using an unpaired Student’s t-test,
assuming equal variances. P < 0.05 was considered
significant.
Results
Increased expression of RAGE, IL-17, and ACT- 1 in
synovial tissues of patients with RA
The expression of RAGE, IL-17, and ACT-1 in synovial
tissues from patients with RA (mild, severe) and patients
with OA was examined by immunochemical staining.
The immunohistochemical staining showed that RAGE,
ACT-1, and IL-17 were expressed strongly in RA syno-
vial tissues. In contrast, only scant expression of those
molecules was observed in OA synovial tissues (Figure
1a). Strong RAGE expression was detected in the syno-
vial lining and sublining layers and the perivascular area
in RA synovial tissues. The severity of synovial inflam-
mation was pathologically assessed [20]. Four synovial
tissues showed mild degree inflammation and four
showed severe inflammation. The positive cell count/
field was evaluated. The positive cell count of RAGE,
Act-1 and IL-17 was higher in synovial tissues with
severe inflammation compared to synovial tissues with
mild inflammation. The co-immunostaining of RAGE
and surface markers of macrophage and FLS was per-
formed. In RA synovial tissues, CD68 (macrophage mar-
ker) and CD55 (FLS marker) (blue) were co-stained
with RAGE (red), which implies that RAGE was
expressed by FLS and macrophages (Figure 1b).
The stimulatory effects of IL-17 and IL-1b on RAGE
production and expression in RA-FLS
Synovial fibroblasts obtained from patients with RA
were incubated with various concentrations of IL-17.
We observed that RAGE mRNA production measured
by real-time PCR increased in RA-FLS following IL-17
treatment (Figure 2a). As shown in Figure 2a, RAGE
expression was strongest when IL-17 was provided at 10
ng/ml (*P< 0.05 vs. untreated cells) and gradually
declined at higher doses. Cell cytotoxicity measured by
LDH activity did not increase with IL-17 in culture
supernatants. Increased RAGE expression was also
observed with immunohistochemical staining or ELISA
after 18 to 48 h of IL-17 treatment in the RA-FLS cul-
tures (Figure 2b, 2c).
To evaluate the effects of other inflammatory cyto-
kines and the combined stimuli of inflammatory cyto-
k i n e so nR A G Ep r o d u c t i o ni nR A - F L S ,F L Sw e r e
cultured with IL-17 (10 ng/ml), TNF-a (5 ng/ml), and
IL-1b (5 ng/ml) or a combination of those cytokines for
18 h (Figure 3a). RAGE mRNA expression was evaluated
by real-time PCR. We observed that RAGE mRNA pro-
duction increased with IL-17 and IL-1b treatment (*P
<0.05 vs. untreated cells) but not by TNF-a.T h ec o m -
bined stimuli of both IL-17 and IL-1b significantly
increased RAGE production compared to IL-17 or IL-1b
alone (#P< 0.05 vs. IL-17 10 ng/ml). TNF-a did not
show the additive effects on RAGE production induced
by IL-17 or IL-1b. Immunohistochemical staining indi-
cated that RAGE expression in RA-FLS also increased
with IL-17, IL-1b, and the combined stimuli of IL-17
and IL-1b ( F i g u r e3 b ) .W ea l s om e a s u r e dR A - F L S
RAGE protein production by Western blot. IL-17 and
IL-1b each enhanced RAGE protein production in RA-
FLS. However, the combination of IL-17 and IL-1b did
not show augmented effects on RAGE protein produc-
tion (Figure 3c).
IL-17-mediated RAGE induction in RA-FLS involves PI3
kinase, STAT3, NF-B, and AP-1
To evaluate the signal transduction pathways involved in
the IL-17-mediated RAGE induction, RA-FLS were pre-
treated with 20 μM LY294002, 50 μM AG490, 10 μM
SB203580, 1 μM PD98059, 10 μM parthenolide, or 10
μM curcumin, and the IL-17 induction of RAGE was
evaluated. The inhibitory effects of various signal mole-
cule inhibitors on the production of RAGE mRNA were
assessed. LY294002, a phosphatidylinositol-3 kinase inhi-
bitor, AG490, a STAT3 inhibitor, partherolide, an NF-
B inhibitor, and curcumin, an activator protein-1 (AP-
1) inhibitor, showed inhibitory effects on the production
of RAGE mRNA upon IL-17 stimulation (Figure 4a; P
<0.05 vs. cells treated with IL-17 alone). In contrast,
SB203580, a p38 MAPK inhibitor, and PD98059, a
MEK1 inhibitor, failed to show inhibitory effects on IL-
17-mediated RAGE mRNA induction. Immmunohisto-
chemical staining showed the inhibitory effects of
LY294002, AG490, partherolide, and curcumin on
RAGE expression (Figure 4b). A Western blot and
immunohistochemical staining of synovial tissues
showed that IL-17 increased activation of phospho
STAT3, phospho IB, phospho c-Jun, and phospho
AKT in RA-FLS (Figure 5). Co-immunostaining of
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Page 4 of 12Figure 1 Immunohistochemical staining of RAGE, Act1 and IL-17.( a) The synovial tissue sections from patients with rheumatoid arthritis and
osteoarthritis were stained with antibodies to RAGE, Act-1, IL-17, and H&E or an isotype-control antibody. The brown color shows the target. (b)
Dual immunohistochemistry labeling using antibody RAGE and CD55 (for fibroblast like synoviocytes) or CD68 (for macrophages). All tissues were
counterstained with hematoxylin (original magnification, x400).
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Page 5 of 12Figure 2 The mRNA of RAGE was increased by IL-17 in a dose-dependent manner in rheumatoid arthritis fibroblast-like synoviocytes
(RA-FLS).( a) RA-FLS were cultured with the indicated doses of IL-17 for 18 h. Total mRNA was extracted and analyzed by real-time PCR with
SYBR Green I. Values are the mean ± SEM from one representative experiment with FLS from four patients with RA. RA-FLS (2 × 10
5) were
cultured with IL-17 for 18 h. Cell viability was assessed by lactate dehydrogenase (LDH) activity. (b) FLS were treated with the same method as
(a). RAGE expression in the FLS was determined using a RAGE-specific antibody. (c) RA-FLS were cultured with the indicated doses of IL-17 for 48
h. RAGE was assessed by ELISA. Values are the mean ± SEM from one representative experiment with FLS from four patients with RA. *P < 0.05,
**P < 0.01 compared to untreated cells.
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Page 6 of 12Figure 3 IL-17 and IL-1b increased RAGE mRNA expression in RA-FLS.( a) RA-FLS were cultured with 10 ng/ml IL-17, 5 ng/ml TNF-a, and 1
ng/ml IL-1b for 24 h, and RAGE mRNA was analyzed by real-time PCR. The lactate dehydrogenase (LDH) concentrations in the culture
supernatants were determined by an activity assay kit. (b) RA-FLS were cultured as in Figure 3a. RAGE expression in the FLS was determined
using a RAGE-specific antibody. The brown color shows the RAGE. (c) RAGE protein expression was identified by Western blot. Values are the
mean ± SEM of triplicate cultures. *P < 0.05 compared to untreated cells and #P < 0.05 compared to IL-17-treated cells.
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Jun, and phospho AKT showed the link between in vitro
signaling molecules and RAGE (Figure 5f).
Act-1 shRNA completely inhibited IL-17-induced RAGE
production in RA-FLS
To identify whether Act-1 is involved in the signal path-
way of IL-17-induced RAGE production and expression,
we tested the effect of Act-1 shRNA on RAGE produc-
tion. We produced Act-1 shRNA and confirmed the
inhibitory effect of Act-1 shRNA on Act-1 expression
(Figure 6a). Act-1 shRNA added to the RA-FLS culture
supernatant completely suppressed the enhanced pro-
duction of RAGE by IL-17 (Figure 6b).
Discussion
An important role for RAGE has been reported in both
OA and RA. In OA cartilage, an accumulation of AGE
and up-regulation of RAGE were noted compared with
normal healthy cartilage [21]. Inflammation-induced car-
tilage hypertrophy is induced by RAGE in OA [22]. In
this study, we observed that RAGE expression was far
stronger in RA synovium than in OA synovium. Drinda
et al.a l s od e t e c t e dR A G Ee x p r e s s i o ni nt h es y n o v i a l
Figure 4 IL-17-mediated RAGE induction in RA-FLS involves PI3 kinase, STAT3, NF-B, and AP-1.( a) RA-FLS were pretreated with 20 μM
LY294002, 50 μM AG490, 10 μM SB203580, 20 μM PD98059, 10 μM parthenolide, or 10 μM curcumin for 30 minutes, and then 10 ng/ml IL-17
was added for 12 h. RAGE mRNA was analyzed by real-time PCR. RA-FLS were cultured as in Figure 4a. The lactate dehydrogenase (LDH)
concentrations in the culture supernatants were determined using an activity assay kit. (b) FLS were treated with same method as (a). RAGE
expression in the FLS was determined using a RAGE-specific antibody. The brown color shows the RAGE. Values are the mean ± SEM of triplicate
cultures. *P < 0.05 compared to inhibitor-treated cells.
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Page 8 of 12Figure 5 IL-17-mediated-RAGE induction in RA-FLS involves PI3kinase, STAT3, NF-kB and AP-1.R A - F L Sw e r ep r e t r e a t e dw i t h5 0μM
AG490 or 10 μM parthenolide for 30 minutes, and then 10 ng/ml IL-17 was added for 12 h. RA-FLS were cultured with 10 ng/ml IL-17. The
protein levels of phosphoSTAT3, phosphoIkB, phosphoC-Jun, and phosphoAKT were analyzed by Western blot. The expression of phosphoSTAT3,
phosphoIkB, phosphoC-Jun, and phosphoAKT on FLS was assessed by immunohistochemical staining using specific antibodies. Co-
immunostaining of RAGE and phospho STAT3, phospho IB, phospho c-Jun, and phospho AKT showed the link between in vitro signaling
molecules and RAGE. Values are the mean ± SEM of triplicate cultures. *P < 0.05, **P < 0.005 compared to IL-17 or inhibitor-treated cells.
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(CD45RO(+)) and some macrophages (CD68(+)) showed
positive immunostaining for RAGE, whereas B cells
were mostly negative. They reported no difference in
staining patterns between the RA and OA samples,
which is not compatible with our observations [23]. The
up-regulation of RAGE in RA synovium may be related
to the abundance of inflammatory cytokines in RA syno-
vial tissue. We observed that IL-1b and IL-17 have sti-
mulatory effects on RAGE expression and production in
RA-FLS. In contrast, TNF-a failed to show stimulatory
effects on RAGE expression and production. The influ-
ence of inflammatory cytokines on RAGE expression in
RA synovial tissue has been previously reported. Suna-
hori et al.r e p o r t e dt h a tR A G Em R N Ae x p r e s s i o ni s
augmented by various cytokines, most potently by IL-1b
[7]. Notably, TNF-a, a central pro-inflammatory cyto-
kine that plays important roles in RA pathogenesis, did
not show strong effects on RAGE expression. In addi-
tion, the inducing effect of IL-17 on RAGE protein
expression was inhibited by TNF-a (Figure 3c). This
observation was compatible with a previous report by
Sunahori et al. [7]. Although TNF-a may counteract the
stimulatory effect of IL-17 on RAGE expression, in
rheumatoid synovium, the expression of RAGE was
increased as the final outcome as we observed in immu-
nohistochemical staining of RA synovial tissues. IL-17
showed stimulatory effects on RAGE expression in FLS
cultures in our experiments and may be relevant to the
over-expression of RAGE on RA synovial tissues. How-
ever, the exact mechanism of RAGE over-expression in
the milieu of various inflammatory cytokines of RA
Figure 6 Act1 shRNA completely inhibited IL-17-induced RAGE production in RA-FLS.( a) RA-FLS were treated with Act-1 shRNA. Act-1
mRNA was analyzed by real-time PCR. (b) RA-FLS were pretreated with Act-1 shRNA for 24 h, and then 10 ng/ml IL-17 was added for 24 h.
RAGE mRNA was analyzed by real-time PCR. *P < 0.05 compared to untreated cells and #P < 0.05 compared to IL-17 treated cells.
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report documenting the effect of IL-17 on RAGE
expression in RA-FLS. The importance of IL-17 in RA
pathogenesis has recently been emphasized. IL-17 sti-
mulates the production and expression of pro-inflamma-
tory cytokines from monocytes/macrophages [24] and
from RA-FLS [25]. Furthermore, IL-17 contributes to
angiogenesis [26] and osteoclastogenesis [27] in RA.
Taken together, IL-17 contributes to RA pathogenesis
due to perpetuations of inflammation to bone erosion
and joint destruction. In our experiment, IL-17 induced
RAGE production as well as RAGE mRNA expression
in RA-FLS in a dose-dependent manner.
The engagement of RAGE stimulates diverse signaling
cascades that regulate the adaptive and innate immune
system [28]. Binding RAGE with its ligands activates
NF-B and results in subsequent activation of pro-
inflammatory responses. Furthermore, the activation of
NF-B results in increased RAGE expression and
increases the number of ligand binding sites, which in
turn sustains NF-B activation. The ability of RAGE to
convert acute cellular activation into a sustained cellular
response contributes to the development of complica-
tions in chronic diseases, such as diabetes and arthro-
sclerosis, and in neurodegenerative diseases [28]. In
chronic inflammatory diseases such as RA, RAGE may
contribute to the augmentation of the pro-inflammatory
loop and sustain the inflammatory response. In our
study, IL-17 was a strong inducer of RAGE in RA-FLS.
IL-17 exerts an important role in inflammatory diseases
both directly and indirectly. The up-regulation of RAGE
is one of the functions of IL-17 for modulating the
inflammatory condition.
We observed that Act-1 played an important role in
IL-17-induced RAGE expression. Act-1 siRNA comple-
tely abrogated the IL-17-induced RAGE expression in
our experiment. IL-17 activates the NF-Ba n dM A P K
pathways and requires TNF receptor associated factor-6
to induce IL-6 [29]. The IL-17 receptor family shares
sequence homology in their intracellular region with
Toll-IL-1 receptor domains and with Act1. The Act1
and IL-17 receptors directly associate via a homotypic
interaction and IL-17. Deficiency of Act1 in fibroblasts
blocks IL-17-induced cytokine and chemokine expres-
sion. The absence of Act1 results in a selective defi-
ciency of IL-17-induced activation of the NF-B
p a t h w a y[ 3 0 ] .W ed o c u m e n t e dt h a tt h ei n d u c t i o no f
RAGE by IL-17 was also Act-1 dependent in RA-FLS.
Blocking RAGE to attenuate diabetic complications
and inflammation has been attempted. Soluble RAGE, a
decoy receptor of RAGE, successfully blocks the binding
of ligand and RAGE in vitro and in vivo [6,31]. Soluble
RAGE reduces the complications of diabetes [31], sup-
presses Alzheimer pathology [32], and improves the
outcome of experimental colitis [5]. Many studies have
suggested that RAGE is a future target for treating
chronic and inflammatory diseases. According to ELISA
results, soluble RAGE level was also increased by IL-17
in our experiment. Soluble RAGE may act as a decoy
receptor but we did not prove the function of soluble
RAGE and cell surface RAGE. It should be further
examined in future study. In our experiment, we deter-
mined that Act-1 could be a possible target regulating
RAGE over-expression in RA. As IL-17 is important in
the pathogenesis of various autoimmune diseases and
chronic diseases, targeting Act-1 needs to be documen-
ted in other pathologic conditions.
Conclusions
In this study, we found that RAGE up-regulation in RA-
FLS was largely IL-17-dependent. As Act-1 is involved
in IL-17-induced RAGE up-regulation, targeting Act-1
could be a promising target for regulating RAGE
expression.
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